Melanoma Flashcards

1
Q

most common type of melanoma

A

superficial spreading

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

nodular melanoma

A

vertical growth
dark blue/black
raised and asymetrical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

superficial spreading melanoma

A

starts flat but becomes irregular and asymetrical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

lentigo maligna melanoma

A

old people
brown / black

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

acral lentiginous melanoma

A

palms, soles, under nail beds
brown stains
most common in non whites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

uveal melanoma

A

in the eye

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

when is radiation reccommended

A

positive lymph nodes
high risk of relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

stage I and II reccommendation

A

surgery (removing the mass)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

stage III first line if no BRAF mutation

A

nivolumab or pembrolizumab
nivolumab / ipilumab but VERY TOXIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

first line stage III if braf

A

dabrafinib / trametinib
vemurafenib / cobimetinib (only v600E)
encorafenib / binimetinib LESS side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

second line Stage III if theyve progressed on an anti PD-1

A

pembrolizumab + ipilumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

who should be tested for BRAF?

A

everyone with metastatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

if we want a BRAF which has fewest side effects

A

encorafinib + binimetinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

which drugs are PD-1 inhibitors

A

nivolumab
pembrolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what moa is ipilumab

A

CTLA-4 inhib

17
Q

atezolizumab and durvalumab are what moa

A

PD-L1 inh

18
Q

what is a consideration with ipilimumab and toxicity after initiation

A

it will look worse before it gets better
need to take all 4 doses and then will see response

19
Q

how many stool per day increase will we hold therapy

A

4-6

20
Q

how many stool per day increase willl we stop therapy

A

7+

21
Q

what do we do if theres a severe immune reaction?

A

discontinue therapy and give high dose steroid